ORIN1001

DRUG3 trials

Sponsors

Orinove, Inc.

Conditions

Advanced Solid TumorEffect of DrugIdiopathic Pulmonary FibrosisMetastatic Breast Cancer

Phase 1

ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

CompletedNCT03950570

Orinove, Inc.Advanced Solid Tumor, Metastatic Breast Cancer

Start: 2019-05-25End: 2023-01-30Updated: 2024-12-31

Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

SuspendedNCT04643769

Orinove, Inc.Idiopathic Pulmonary Fibrosis

Start: 2021-02-09End: 2025-12-30Target: 24Updated: 2025-05-30

Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.

CompletedNCT05154201

Orinove, Inc.Effect of Drug

Start: 2020-07-01End: 2025-01-30Updated: 2025-05-30

Related Papers

Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors

Frontiers in Pharmacology2024-03-049 citations

Decoding the proteostasis network in resistance to KRAS inhibitors

The Innovation2023-10-182 citations

Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.

Journal of Clinical Oncology2023-06-0111 citations

A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.

Journal of Clinical Oncology2021-05-2024 citations